0001209191-20-005130.txt : 20200128
0001209191-20-005130.hdr.sgml : 20200128
20200128161300
ACCESSION NUMBER: 0001209191-20-005130
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200124
FILED AS OF DATE: 20200128
DATE AS OF CHANGE: 20200128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Allen Patricia L
CENTRAL INDEX KEY: 0001348587
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 20554348
BUSINESS ADDRESS:
BUSINESS PHONE: 978-687-6988
MAIL ADDRESS:
STREET 1: 7 ASHFORD LANE
CITY: ANDOVER
STATE: MA
ZIP: 01810
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-24
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001348587
Allen Patricia L
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
1
0
0
0
Common Stock
2020-01-24
4
C
0
25000
3.95
A
25000
D
Common Stock
2020-01-24
4
S
0
17804
65.933
D
7196
D
Common Stock
2020-01-24
4
S
0
6496
66.5491
D
700
D
Common Stock
2020-01-24
4
S
0
700
67.3586
D
0
D
Stock Option (Right to Buy)
3.95
2020-01-24
4
A
0
25000
0.00
A
2026-09-26
Common Stock
25000
10233
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.25 to $66.24, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.25 to $67.12, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.29 to $67.45, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This stock option award was issued pursuant to the Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 27, 2016, subject to continued service through such dates.
/s/ Thomas P. Kelly, Attorney-in-Fact
2020-01-28